NSCLC
526
135
182
122
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
38 trials with published results (7%)
Research Maturity
122 completed trials (23% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.9%
52 terminated out of 526 trials
70.1%
-16.4% vs benchmark
9%
49 trials in Phase 3/4
31%
38 of 122 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 122 completed trials
Clinical Trials (526)
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng and Resection
A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prognostic Value in Patients With NSCLC
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Crizotinib Continuation Clinical Study